인쇄하기
취소

Dong-A licenses Zydena to Meiji Seika

Published: 2011-12-21 06:57:00
Updated: 2011-12-21 06:57:00
Dong-A Pharmaceutical Co. Monday announced the signing of an licensing-out agreement with Meiji Seika Pharma, granting Meiji exclusive rights to develop and commercialize Dong-A’s phosphodiesterase-5 inhibitor Zydena (udenafil) for urological indications, with an initial focus on benign prostatic hyperplasia (BPH)

The financial terms of the tie-up were not disclosed, but Meiji is said to pay...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.